Earnings summaries and quarterly performance for PERRIGO Co.
Executive leadership at PERRIGO Co.
Patrick Lockwood-Taylor
Detailed
President and Chief Executive Officer
CEO
AL
Abbie Lennox
Detailed
Executive Vice President and Chief Scientific Officer
CA
Charles Atkinson
Detailed
Executive Vice President, General Counsel and Company Secretary
DB
David Ball
Detailed
Executive Vice President and Chief Brand and Digital Officer
EB
Eduardo Bezerra
Detailed
Executive Vice President and Chief Financial Officer
MW
Matt Winterman
Detailed
Executive Vice President, Product Supply, Operations Strategy & Transformation Officer
RK
Roberto Khoury
Detailed
Executive Vice President and Chief Commercial Officer
Board of directors at PERRIGO Co.
AK
Adriana Karaboutis
Detailed
Director
AM
Albert Manzone
Detailed
Director
BA
Bradley Alford
Detailed
Director
DO
Donal O'Connor
Detailed
Director
GP
Geoffrey Parker
Detailed
Director
JK
Jeffrey Kindler
Detailed
Director
JS
Jonas Samuelson
Detailed
Director
JB
Julia Brown
Detailed
Director
KE
Kevin Egan
Detailed
Director
OA
Orlando Ashford
Detailed
Chairman of the Board
Research analysts who have asked questions during PERRIGO Co earnings calls.
DB
Daniel Biolsi
Hedgeye Risk Management
5 questions for PRGO
Also covers: BRCC, STKL
Susan Anderson
Canaccord Genuity Group
5 questions for PRGO
Also covers: BODI, CDXC, COTY +13 more
KD
Keith Devas
Jefferies Financial Group Inc.
4 questions for PRGO
Also covers: KVUE, PBH
Ethan Brown
JPMorgan Chase & Co.
3 questions for PRGO
Also covers: OGN
KW
Korinne Wolfmeyer
Piper Sandler & Co.
2 questions for PRGO
Also covers: AIRS, BBWI, CHD +14 more
CS
Christopher Schott
JPMorgan Chase & Co.
1 question for PRGO
Also covers: ABBV, AMGN, AMRX +15 more
KD
Keith Davos
Jefferies
1 question for PRGO
Also covers: IDXX, PBH
SM
Sarah Morin
Piper Sandler Companies
1 question for PRGO
Also covers: OLLI
Recent press releases and 8-K filings for PRGO.
Perrigo Reports Q4 2025 Results and Provides 2026 Outlook
PRGO
Guidance Update
Layoffs
M&A
- Perrigo reported a $1.3 billion goodwill impairment charge in 2025 and projects a potential additional non-cash goodwill impairment charge of up to $350 million in Q1 2026.
- For 2026, the company expects CORE Perrigo organic net sales growth of -3.5% to +0.5% and CORE EPS of $2.25-$2.55, reflecting challenging market conditions and temporary impacts from plant under absorption.
- A new two-year operational enhancement program is being implemented, including a global workforce reduction of approximately 7%, targeting annualized pre-tax savings of $80 million-$100 million.
- The sale of the dermacosmetics business is anticipated to close in Q2 2026, with proceeds used for debt reduction, while a strategic review of the infant formula business is ongoing.
- Perrigo ended 2025 with a net leverage ratio of 4 times and aims to reduce it to below 3 times over the next 2-3 years, with 2026 leverage expected to be similar to 2025.
1 day ago
Perrigo Reports Q4 and Full Year 2025 Results and Provides 2026 Outlook
PRGO
Earnings
Guidance Update
M&A
- Perrigo reported FY 2025 all-in EPS of $2.75, a 7% increase, and CORE EPS up 14%, driven by operational rigor and disciplined cost management despite soft market conditions.
- For 2026, the company forecasts CORE organic net sales growth of -3.5% to +0.5% and CORE EPS between $2.25 and $2.55, noting an approximate $0.60 negative impact to all-in EPS from plant under absorption.
- A new two-year operational enhancement program is expected to deliver $80 million-$100 million in annualized pre-tax savings, including a global workforce reduction of approximately 7%.
- The sale of the dermacosmetics business is anticipated to close in Q2 2026, with proceeds allocated to debt reduction, while a strategic review of the infant formula business remains ongoing.
1 day ago
Perrigo Reports Q4 and Full Year 2025 Results, Provides 2026 Outlook
PRGO
Earnings
Guidance Update
Layoffs
- Perrigo reported full year 2025 All-in EPS of $2.75 and CORE EPS growth of 14%, with Q4 CORE organic net sales declining 2% due to continued market weakness.
- For 2026, the company forecasts CORE EPS in the range of $2.25-$2.55 and All-in EPS between $2.00-$2.30, anticipating a $0.60 negative impact to All-in EPS from plant under absorption and a second-half weighted CORE EPS phasing (65%-70%).
- Perrigo launched a new operational enhancement program targeting $80 million-$100 million in annualized pre-tax savings, with 80% expected in 2026, and a global workforce reduction of approximately 7%.
- The company ended 2025 with a net leverage ratio of 4 times, expecting it to be in line with or slightly better than 2025 by year-end 2026, partly due to proceeds from the dermacosmetics business sale anticipated in Q2 2026.
- Perrigo will introduce new reporting segments (Self Care, Specialty Care, and Infant Formula) starting Q1 2026 and is conducting an ongoing strategic review of its infant formula business.
1 day ago
Perrigo Co. Reports Q4 and FY2025 Results, Provides FY2026 Outlook
PRGO
Earnings
Guidance Update
M&A
- Perrigo Co. reported FY2025 All-In Net Sales of $4.3 billion and Adjusted EPS of $2.75, meeting the midpoint of its updated outlook range.
- For Q4 2025, the company recorded All-In Net Sales of $1,110 million and Adjusted EPS of $0.77.
- The company made significant progress on its 'Three-S' Plan in 2025, including growing U.S. Store Brand OTC share by +0.6pt and achieving $320 million in benefits from efficiency initiatives.
- Perrigo provided an FY2026 All-In Adjusted EPS outlook of $2.00 to $2.30 and projects All-In Net Sales growth of -5.5% to -1.5%.
- As part of its streamlining efforts, the company announced the divestiture of its Dermacosmetics business and is assessing its Infant Formula and Oral Care portfolios.
1 day ago
Perrigo Reports Q4 and Fiscal Year 2025 Results, Issues FY 2026 Outlook
PRGO
Earnings
Guidance Update
M&A
- Perrigo reported Q4 2025 net sales of $1.11 billion, a 2.5% decrease year-over-year, and FY 2025 net sales of $4.25 billion, a 2.8% decrease year-over-year.
- The company reported a diluted EPS of $(10.20) for Q4 2025 and $(10.12) for FY 2025, primarily due to a $1.3 billion goodwill impairment charge in Q4 2025. Adjusted EPS for Q4 2025 was $0.77 and for FY 2025 was $2.75.
- For FY 2026, Perrigo issued an 'All In' outlook projecting net sales to decrease -5.5% to -1.5% and adjusted diluted EPS between $2.00 and $2.30. The 'CORE' outlook (excluding Infant Formula and previously announced divestitures) anticipates net sales growth of -3.0% to +1.0% and adjusted EPS of $2.25 to $2.55.
- Perrigo launched a new operational enhancement program targeting $80 million to $100 million in pre-tax annualized savings by the end of FY2027 , and agreed to divest its Dermacosmetics business for up to €327 million, with the transaction anticipated to close in Q2 2026.
2 days ago
Perrigo Faces Class Action Lawsuit Over Infant Formula Business Allegations
PRGO
Legal Proceedings
- A class action lawsuit has been filed against Perrigo Company plc (NYSE: PRGO), with a class period from February 27, 2023, to November 4, 2025.
- The complaint alleges that the infant formula business acquired from Nestlé suffered from significant underinvestment and manufacturing deficiencies, requiring substantial capital and operational expenditures beyond stated estimates.
- It is further alleged that Perrigo's financial results, including earnings and cash flow, were overstated, and the company's positive statements were materially misleading.
- The Lead Plaintiff Deadline for this class action is January 16, 2026.
Jan 6, 2026, 5:25 PM
Perrigo Faces Class Action Lawsuit Over Infant Formula Business Allegations
PRGO
Legal Proceedings
- A class action lawsuit has been filed against Perrigo Company plc, covering a Class Period from February 27, 2023, to November 4, 2025.
- The complaint alleges that the infant formula business acquired from Nestlé suffered from significant underinvestment in maintenance, operational improvements, and repairs, as well as manufacturing deficiencies.
- It is claimed that Perrigo needed to make substantial capital and operational expenditures beyond stated estimates to remediate the infant formula business, which resulted in overstated financial results, including earnings and cash flow.
- The deadline for investors to file a lead plaintiff motion in this class action is January 16, 2026.
Dec 18, 2025, 5:09 PM
Perrigo Faces Class Action Lawsuit Following Disappointing Q3 Results and Infant Formula Business Review
PRGO
Legal Proceedings
Guidance Update
Demand Weakening
- A class action lawsuit has been initiated against Perrigo Company plc, covering a class period from February 27, 2023, to November 4, 2025, with a lead plaintiff deadline of January 16, 2026.
- The complaint alleges that Perrigo failed to disclose significant underinvestment and manufacturing deficiencies in its infant formula business, requiring substantial additional capital expenditures and resulting in overstated financial results.
- On November 5, 2025, Perrigo announced disappointing financial results for the third quarter ended September 27, 2025, and slashed its fiscal year 2025 outlook due to infant formula industry dynamics.
- The company is also initiating a strategic review of its infant formula business, reassessing a previously announced $240 million investment, which caused the stock price to fall 25.2% to $15.10 per share on November 5, 2025.
Dec 15, 2025, 9:08 PM
Perrigo Company plc Faces Class Action Lawsuit Over Infant Formula Business
PRGO
Legal Proceedings
Guidance Update
Demand Weakening
- A class action lawsuit has been filed against Perrigo Company plc (PRGO) and its executives for alleged violations of the Securities Exchange Act of 1934 during the Class Period of February 27, 2023, and November 4, 2025.
- The lawsuit alleges that Perrigo made false and/or misleading statements regarding its infant formula business, acquired from Nestlé, specifically concerning underinvestment, required substantial remediation expenditures, and manufacturing deficiencies.
- The complaint highlights several disclosures, including a February 27, 2024, announcement of $35 million to $45 million in remediation costs and a 50% decline in EPS.
- On November 5, 2025, Perrigo announced a strategic review of its infant formula business, reassessing a $240 million investment, and slashed its fiscal year 2025 outlook for net sales growth and adjusted diluted earnings per share.
- Investors with substantial losses have until January 16, 2026, to seek appointment as lead plaintiff.
Dec 15, 2025, 12:20 PM
Perrigo Company plc Faces Class Action Lawsuit Over Infant Formula Business
PRGO
Legal Proceedings
Guidance Update
Profit Warning
- Robbins Geller Rudman & Dowd LLP has announced a class action lawsuit against Perrigo Company plc (PRGO) and certain executives on behalf of purchasers or acquirers of PRGO securities between February 27, 2023, and November 4, 2025.
- The lawsuit alleges that Perrigo made false or misleading statements and failed to disclose significant issues with its acquired Nestlé infant formula business, including underinvestment, substantial remediation costs, and manufacturing deficiencies, which led to overstated financial results.
- The company's stock price experienced significant declines following disclosures related to the infant formula business, including a more than 15% fall on February 27, 2024, a nearly 10% fall on May 7, 2024, a more than 11% fall on August 6, 2025, and a more than 25% fall on November 5, 2025.
- On November 5, 2025, Perrigo announced a strategic review of its infant formula business and slashed its fiscal year 2025 outlook, revising net sales growth guidance to -2.5% to -3% (from 0% to 3%) and adjusted diluted earnings per share to $2.70 to $2.80 (from $2.90 to $3.10).
- Investors who suffered substantial losses have until January 16, 2026, to seek appointment as lead plaintiff in the lawsuit.
Dec 6, 2025, 2:50 PM
Quarterly earnings call transcripts for PERRIGO Co.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more